Braidwell LP Raises Stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

Braidwell LP lifted its holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 122.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,147,676 shares of the company's stock after buying an additional 631,950 shares during the quarter. Braidwell LP owned about 3.28% of Oruka Therapeutics worth $22,253,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in ORKA. Vanguard Group Inc. raised its stake in shares of Oruka Therapeutics by 4,161.2% in the fourth quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company's stock worth $31,231,000 after acquiring an additional 1,572,853 shares during the last quarter. Franklin Resources Inc. bought a new position in Oruka Therapeutics in the 3rd quarter worth approximately $17,661,000. Geode Capital Management LLC acquired a new position in Oruka Therapeutics during the 3rd quarter worth $343,000. Wellington Management Group LLP boosted its position in Oruka Therapeutics by 15.8% in the 4th quarter. Wellington Management Group LLP now owns 95,089 shares of the company's stock valued at $1,844,000 after buying an additional 12,952 shares during the last quarter. Finally, Barclays PLC bought a new position in Oruka Therapeutics in the 4th quarter valued at $1,446,000. Institutional investors and hedge funds own 56.44% of the company's stock.

Oruka Therapeutics Stock Performance

NASDAQ:ORKA traded down $0.21 on Friday, reaching $9.54. The company's stock had a trading volume of 104,045 shares, compared to its average volume of 231,593. The firm has a market cap of $357.19 million, a PE ratio of -1.52 and a beta of 0.25. The business's 50-day moving average price is $9.95 and its two-hundred day moving average price is $15.56. Oruka Therapeutics, Inc. has a 1-year low of $5.49 and a 1-year high of $31.13.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last announced its earnings results on Thursday, March 6th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.19. As a group, sell-side analysts expect that Oruka Therapeutics, Inc. will post -3.41 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on ORKA shares. Wedbush reaffirmed an "outperform" rating and set a $40.00 price target on shares of Oruka Therapeutics in a research note on Friday, March 7th. Wolfe Research initiated coverage on shares of Oruka Therapeutics in a research report on Tuesday, February 4th. They set an "outperform" rating and a $20.00 target price on the stock. Finally, HC Wainwright restated a "buy" rating and issued a $45.00 price objective on shares of Oruka Therapeutics in a report on Friday, February 7th. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Oruka Therapeutics currently has an average rating of "Buy" and a consensus target price of $39.86.

Insider Buying and Selling at Oruka Therapeutics

In other news, major shareholder Venrock Healthcare Capital Par acquired 88,794 shares of the business's stock in a transaction that occurred on Friday, February 14th. The stock was acquired at an average price of $11.44 per share, with a total value of $1,015,803.36. Following the completion of the transaction, the insider now directly owns 4,148,428 shares of the company's stock, valued at $47,458,016.32. This trade represents a 2.19 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have purchased a total of 98,339 shares of company stock valued at $1,128,456 in the last three months. 22.67% of the stock is currently owned by company insiders.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.